137 related articles for article (PubMed ID: 32762307)
1. Serine 897 Phosphorylation of EPHA2 Is Involved in Signaling of Oncogenic ERK1/2 Drivers in Thyroid Cancer Cells.
Allocca C; Cirafici AM; Laukkanen MO; Castellone MD
Thyroid; 2021 Jan; 31(1):76-87. PubMed ID: 32762307
[No Abstract] [Full Text] [Related]
2. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
3. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
4. Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin.
Shang X; Lin X; Howell SB
Cell Commun Signal; 2014 Oct; 12():59. PubMed ID: 25344320
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
Barquilla A; Lamberto I; Noberini R; Heynen-Genel S; Brill LM; Pasquale EB
Mol Biol Cell; 2016 Sep; 27(17):2757-70. PubMed ID: 27385333
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation.
Hamaoka Y; Negishi M; Katoh H
Biochem Biophys Res Commun; 2018 May; 499(4):920-926. PubMed ID: 29626472
[TBL] [Abstract][Full Text] [Related]
8. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C phosphorylates the EphA2 receptor on serine 892 in the regulatory linker connecting the kinase and SAM domains.
Gehring MP; Pasquale EB
Cell Signal; 2020 Sep; 73():109668. PubMed ID: 32413552
[TBL] [Abstract][Full Text] [Related]
10. The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.
Rusciano MR; Salzano M; Monaco S; Sapio MR; Illario M; De Falco V; Santoro M; Campiglia P; Pastore L; Fenzi G; Rossi G; Vitale M
Endocr Relat Cancer; 2010 Mar; 17(1):113-23. PubMed ID: 19903742
[TBL] [Abstract][Full Text] [Related]
11. S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties.
Li JY; Xiao T; Yi HM; Yi H; Feng J; Zhu JF; Huang W; Lu SS; Zhou YH; Li XH; Xiao ZQ
Cancer Lett; 2019 Mar; 444():162-174. PubMed ID: 30583071
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of KIBRA by the extracellular signal-regulated kinase (ERK)-ribosomal S6 kinase (RSK) cascade modulates cell proliferation and migration.
Yang S; Ji M; Zhang L; Chen Y; Wennmann DO; Kremerskothen J; Dong J
Cell Signal; 2014 Feb; 26(2):343-51. PubMed ID: 24269383
[TBL] [Abstract][Full Text] [Related]
13. Ionizing radiation induces EphA2 S897 phosphorylation in a MEK/ERK/RSK-dependent manner.
Graves PR; Din SU; Ashamalla M; Ashamalla H; Gilbert TSK; Graves LM
Int J Radiat Biol; 2017 Sep; 93(9):929-936. PubMed ID: 28705041
[TBL] [Abstract][Full Text] [Related]
14. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation.
Hamaoka Y; Negishi M; Katoh H
Cell Signal; 2016 Aug; 28(8):937-45. PubMed ID: 27132626
[TBL] [Abstract][Full Text] [Related]
15. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
Garcia-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Herrero-Martín D; Huertas-Martinez J; Lagares-Tena L; Alba-Pavón P; Hontecillas-Prieto L; Mora J; de Álava E; Rello-Varona S; Giangrande PH; Tirado OM
Int J Cancer; 2018 Sep; 143(5):1188-1201. PubMed ID: 29582409
[TBL] [Abstract][Full Text] [Related]
16. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
17. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
18. Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer.
Moyano-Galceran L; Pietilä EA; Turunen SP; Corvigno S; Hjerpe E; Bulanova D; Joneborg U; Alkasalias T; Miki Y; Yashiro M; Chernenko A; Jukonen J; Singh M; Dahlstrand H; Carlson JW; Lehti K
EMBO Mol Med; 2020 Apr; 12(4):e11177. PubMed ID: 32115889
[TBL] [Abstract][Full Text] [Related]
19. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
20. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
